

ABSTRACT

Provided is a method for treating ALK-positive non-small cell lung cancer in a subject by means of administering a compound A or a pharmaceutically acceptable salt thereof to the subject. Further provided is a method for treating ROS1-positive non-small cell lung cancer in a subject by means of administering compound A or a pharmaceutically acceptable salt thereof to the subject.

